Inhibitor Therapeutics Inc., a biotechnology company headquartered in Tampa, Florida, is actively engaged in the development of innovative therapies targeting various types of cancer, with a specific emphasis on skin, lung, and prostate cancers. As a clinical-stage biopharmaceutical entity, Inhibitor Therapeutics has been dedicated to the discovery, development, and commercialization of cancer therapeutics in the United States since its inception in 1997.
The company operates within the Health Care sector, specifically under the Pharmaceuticals industry. It is listed on the OTC Bulletin Board, with its financial transactions conducted in USD. As of November 11, 2025, the close price of Inhibitor Therapeutics Inc. was recorded at $0.05. Over the past year, the company’s stock has experienced fluctuations, reaching a 52-week high of $0.09 on November 18, 2024, and a 52-week low of $0.034 on May 13, 2025.
Inhibitor Therapeutics Inc. has a market capitalization of $8,620,000 USD. The company’s financial metrics indicate a price-to-earnings (P/E) ratio of -2.5, reflecting its current earnings status. This negative P/E ratio is not uncommon for companies in the biotechnology sector, particularly those in the clinical stages of drug development, where profitability is not yet realized.
The company’s strategic focus on developing therapies for skin, lung, and prostate cancers positions it within a critical area of oncology research. These cancer types represent significant health challenges, and advancements in treatment options are highly sought after in the medical community. Inhibitor Therapeutics’ commitment to innovation in this field underscores its potential to contribute meaningfully to cancer treatment advancements.
As Inhibitor Therapeutics Inc. continues its clinical and commercial endeavors, it remains a notable player in the biopharmaceutical landscape, driven by its mission to deliver effective cancer therapies to patients in need. The company’s ongoing research and development efforts are crucial for its future growth and success in the competitive pharmaceutical industry.
